Get the Stockscreener App
2.6284
0.82%
-0.0216
Lipocine Inc stock is traded at $2.6284, with a volume of 12,115.
It is down -0.82% in the last 24 hours and down -21.54% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$2.65
Open:
$2.57
24h Volume:
12,115
Relative Volume:
0.39
Market Cap:
$14.09M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-0.8618
EPS:
-3.05
Net Cash Flow:
$-11.88M
1W Performance:
-4.42%
1M Performance:
-21.54%
6M Performance:
-21.31%
1Y Performance:
-56.84%
1-Day Range:
$2.57
$2.6367
1-Week Range:
$2.57
$2.80
52-Week Range:
$2.57
$6.1564
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.60 | 14.36M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.09 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.50 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.60 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.67 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine (NASDAQ: LPCN) shows LPCN 2401 reduces liver fat at 12 weeks, MRI-PDFF data - Stock Titan
Will Lipocine Inc. stock outperform value stocksEarnings Beat & Accurate Technical Buy Alerts - newser.com
Lipocine Presents Promising LPCN 2401 Data at ObesityWeek - TipRanks
Lipocine Inc Presents LPCN 2401 Clinical Data at ObesityWeek® - TradingView
How Lipocine Inc. stock reacts to inflationary pressures2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
Will Lipocine Inc. stock go up soonGlobal Markets & Smart Swing Trading Alerts - newser.com
Lipocine Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
How Lipocine Inc. stock performs after earningsJuly 2025 Price Swings & Expert Verified Movement Alerts - newser.com
Why analysts upgrade Lipocine Inc. stockJuly 2025 Decliners & Advanced Technical Analysis Signals - newser.com
Is Lipocine Inc. stock a safe buy before earningsJuly 2025 News Drivers & Free High Accuracy Swing Entry Alerts - newser.com
Is Lipocine Inc. stock trading near support levelsEarnings Risk Report & Consistent Return Strategy Ideas - newser.com
How to build a dashboard for Lipocine Inc. stockEarnings Overview Report & Free Technical Pattern Based Buy Signals - newser.com
Smart tools for monitoring Lipocine Inc.’s price actionJuly 2025 Opening Moves & Fast Moving Trade Plans - newser.com
Will a bounce in Lipocine Inc. offer an exitMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Lipocine, Inc. Stock Plummets to New 52-Week Low of $2.57 - Markets Mojo
Is Lipocine Inc. stock attractive for long term wealth buildingWeekly Market Summary & Momentum Based Trading Ideas - newser.com
What margin trends mean for Lipocine Inc. stockJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - fcp.pa.gov.br
Is Lipocine Inc. stock dividend yield sustainableRecession Risk & Free Fast Entry Momentum Trade Alerts - Fundação Cultural do Pará
How risky is Lipocine Inc. stock now2025 Historical Comparison & Weekly Stock Performance Updates - fcp.pa.gov.br
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):